Featured Research

from universities, journals, and other organizations

New heart assist pump allows minimally invasive approach

Date:
April 22, 2014
Source:
Vanderbilt University Medical Center
Summary:
Sometimes smaller is better. This is especially true of left ventricular assist devices, the mechanically operated heart pumps that are implanted in heart failure patients to bridge them to transplantation. The HVAD Pump is a miniaturized, full output device designed to be implanted in the pericardial space. It sits inside the chest and connects directly to the heart. No abdominal dissection is required in the implant procedure.

The new HeartWare left ventricular assist device is implanted through a minimally invasive approach and sits inside the chest, connecting directly to the heart.
Credit: Image courtesy of HeartWare

Sometimes smaller is better. This is especially true of left ventricular assist devices, the mechanically operated heart pumps that are implanted in heart failure patients to bridge them to transplantation.

Related Articles


Vanderbilt Heart and Vascular Institute (VHVI) was the first facility in Tennessee to implant the miniaturized HeartWare HVAD Pump through a minimally invasive approach known as a thoracotomy, a small incision on the side of the chest.

The HVAD Pump is a miniaturized, full output device designed to be implanted in the pericardial space. It sits inside the chest and connects directly to the heart. No abdominal dissection is required in the implant procedure.

Last year, Simon Maltais, M.D., assistant professor of Cardiac Surgery and director of the Heart Transplant and Ventricular Support Program, traveled to the University Heart Center in Leipzig, Germany, to observe Martin Strueber, M.D., and Jan Schmitto, M.D., of Hanover, Germany, as they implanted the HeartWare device. They are now considered pioneers of the minimally invasive LVAD approach.

Over the last year, VHVI became the largest minimally invasive LVAD center in the United States.

Now, physicians from all over the country come to Vanderbilt Heart to watch Maltais at work.

"They come and visit every month. We are getting a lot of attention," he said.

To date, Maltais has implanted 50 HeartWare devices, 40 percent of them minimally invasively, which requires a small 4-6 cm incision. This approach avoids opening the chest through a sternotomy, thus decreasing OR time, risk of perioperative bleeding and infection.

"We try to minimize splitting the sternum, which can be very traumatic. This facilitates the reoperation for the eventual heart transplant. It's a very big advantage," Maltais said.

Combined with another LVAD device known HeartMate II, which VHVI started using in 2008, Vanderbilt performed 82 LVAD procedures in 2013, placing it in the top five medical centers in the country for the number of implants. All told, LVAD survival rates are at 90 percent at Vanderbilt, Maltais said.

The HeartMate II is a high-speed axial flow rotary blood pump. It drains blood continuously from the left ventricle to the aorta by the action of the internal rotor, leading to improved long-term performance.

An article that appeared recently in The New England Journal of Medicine outlined an increased rate of pump thrombosis (blood clots) with the HeartMate II.

Vanderbilt, which has a collaborative relationship with the Mayo Clinic and the University of Michigan to study LVAD outcomes, had not observed this trend. Maltais and John Stulak, M.D., of the Mayo Clinic, studied the outcomes from 516 HeartMate II pump implants performed at the three institutions and submitted their results to the NEJM.

Their letter, written in response to the original article, appeared in the April 10 issue of the journal.

While the group's findings confirmed a similar peak in pump thrombosis in 2012, it unanimously observed a decrease in 2013, according to the NEJM letter.

"These observations were found consistent at each individual center before combining data. While the field is indebted to the report by Starling et al, we have observed a different trajectory in confirmed pump thrombosis incidence more recently," the authors write.

"While we believe this important information should be available to readers, it reaffirms the need to standardize patient management in this challenging population."

Vanderbilt successfully reduced the rate of pump thrombosis associated with the HeartMate II by adjusting its post-operative management on treatment of blood pressure, using more aggressive anticoagulation therapy and managing pump speed differently.

"This work will be widely cited in the upcoming years and proves our ability to be in the top advanced heart failure centers in the country. Our advanced heart failure research program is very productive and is part of making the field progress," Maltais said.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. The original article was written by Kathy Whitney. Note: Materials may be edited for content and length.


Journal Reference:

  1. Randall C. Starling, Nader Moazami, Scott C. Silvestry, Gregory Ewald, Joseph G. Rogers, Carmelo A. Milano, J. Eduardo Rame, Michael A. Acker, Eugene H. Blackstone, John Ehrlinger, Lucy Thuita, Maria M. Mountis, Edward G. Soltesz, Bruce W. Lytle, Nicholas G. Smedira. Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis. New England Journal of Medicine, 2014; 370 (1): 33 DOI: 10.1056/NEJMoa1313385

Cite This Page:

Vanderbilt University Medical Center. "New heart assist pump allows minimally invasive approach." ScienceDaily. ScienceDaily, 22 April 2014. <www.sciencedaily.com/releases/2014/04/140422202051.htm>.
Vanderbilt University Medical Center. (2014, April 22). New heart assist pump allows minimally invasive approach. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2014/04/140422202051.htm
Vanderbilt University Medical Center. "New heart assist pump allows minimally invasive approach." ScienceDaily. www.sciencedaily.com/releases/2014/04/140422202051.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins